Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Adriana Romagnino"'
Autor:
Mohammed A. Alghamdi, Carla P. Amaro, Richard Lee‐Ying, Hao‐Wen Sim, Haider Samwi, Kelvin K. Chan, Jennifer J. Knox, Yoo‐Joung Ko, Mina Swiha, Eugene Batuyong, Adriana Romagnino, Winson Y. Cheung, Vincent C. Tam, the Hepatocellular Carcinoma ‐ Cancer Health Outcomes Research Database (HCC ‐ CHORD) Consortium
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4918-4928 (2020)
Abstract Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mea
Externí odkaz:
https://doaj.org/article/f30b00a8c00b40719fb7ffe444f5c912
Autor:
Haider H. Samawi, Hao‐Wen Sim, Kelvin K. Chan, Mohammad A. Alghamdi, Richard M. Lee‐Ying, Jennifer J. Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo‐Joung Ko, Janine M. Davies, Howard J. Lim, Winson Y. Cheung, Vincent C. Tam, the CHORD Consortium
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2816-2825 (2018)
Abstract Several systems (tumor‐node‐metastasis [TNM], Barcelona Clinic Liver Cancer [BCLC], Okuda, Cancer of the Liver Italian Program [CLIP], and albumin–bilirubin grade [ALBI]) were developed to estimate the prognosis of patients with hepato
Externí odkaz:
https://doaj.org/article/2a723d203a9a4244bf3fd0d5668b1cac
Autor:
Yoo-Joung Ko, Winson Y. Cheung, Vincent C. Tam, Eugene Batuyong, Carla P Amaro, Richard M. Lee-Ying, Mohammed Abdulrahman Alghamdi, Jennifer J. Knox, Haider Samwi, Mina Swiha, Kelvin K. W. Chan, Hao-Wen Sim, Adriana Romagnino
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4918-4928 (2020)
Cancer Medicine
Cancer Medicine
Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052a2c3a401bfc76abd274010273d710
https://doaj.org/article/f30b00a8c00b40719fb7ffe444f5c912
https://doaj.org/article/f30b00a8c00b40719fb7ffe444f5c912
Autor:
Haider H Samawi, Yoo-Joung Ko, Hao-Wen Sim, Kelvin K. W. Chan, Jennifer J. Knox, Winson Y. Cheung, Adriana Romagnino, Eugene Batuyong, Vincent C. Tam, Mohammed Abdullah Alghamdi, Richard M. Lee-Ying, Parneet Gill
Publikováno v:
Annals of Oncology. 28:v238
e15653 Background: Several staging systems and models (TNM, BCLC, Okuda, CLIP and ALBI) have been developed to estimate the prognosis of patients with HCC. Most of these were developed prior to the prevalent use of sorafenib. The purpose of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565c19f94426a0c5b71782ee9d495826
https://doi.org/10.1093/annonc/mdx369.084
https://doi.org/10.1093/annonc/mdx369.084
Autor:
Winson Y. Cheung, Vincent C. Tam, Richard M. Lee-Ying, Mohammed Abdullah Alghamdi, Yoo-Joung Ko, Hao-Wen Sim, Eugene Batuyong, Adriana Romagnino, Haider Samawi, Jennifer J. Knox, Kelvin K. W. Chan, Mina Swiha
Publikováno v:
Journal of Clinical Oncology. 35:4084-4084
4084 Background: The SHARP trial showed that S improves survival in advanced HCC. Full dose (FD) S at 400mg bid can be difficult to tolerate, so some clinicians begin with a reduced dose (RD) & escalate as tolerated to maximum dose. The purpose of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a6fc3e1f82987ff45b1c45056215493
https://doi.org/10.1200/jco.2017.35.15_suppl.4084
https://doi.org/10.1200/jco.2017.35.15_suppl.4084